Clinical Evaluation
An elevated or changing PSA, examination finding, symptom, or other concern may lead to further assessment.
Prostate Cancer Pathology Support
Understanding Your Prostate Cancer Pathology Report
Get a clearer explanation of the diagnosis, Gleason score, Grade Group, percentage of pattern 4, number and extent of positive biopsy cores, intraductal or cribriform findings, margins, extraprostatic extension, seminal-vesicle invasion, lymph nodes, and biomarker results documented in your report.
This educational consultation explains your existing written pathology report. It does not provide a new diagnosis, written report, official document, treatment plan, or replacement for your treating clinicians.
Understand what your report documentsAnd what may still depend on imaging, PSA, surgery, biomarker testing, or other clinical information.
Board-Certified PathologistProfessional pathology-report guidance
Secure Virtual AppointmentMeet online from the comfort of home
Patient-Friendly ExplanationClear language for complex report findings
Educational SupportNot a replacement for medical advice
Understanding the Process
How a Prostate Cancer Diagnosis Is Established
PSA, examination, and imaging can identify a reason for further evaluation, but prostate cancer is usually diagnosed by microscopic examination of tissue. The report’s content depends on whether the specimen is a needle biopsy, TURP tissue, or a radical prostatectomy.
MRI and Tissue Sampling
MRI may help identify targets, while systematic and targeted needle cores collect tissue from specified prostate sites.
Pathology Diagnosis
The pathologist identifies the tumor type and reports Gleason patterns, Gleason score, Grade Group, and tumor extent in the sampled cores.
Wider Clinical Assessment
PSA, imaging, examination, biopsy findings, health history, and any later surgical pathology are considered together by the care team.
PSA is not a pathology diagnosis. PSA is measured in blood. The tissue report provides microscopic findings, while clinical stage and complete risk assessment use information beyond the pathology report.
Different Reports, Different Questions
Needle-Biopsy Versus Radical-Prostatectomy Pathology
A biopsy samples selected areas of the prostate and establishes the diagnosis and grade in those cores. A radical prostatectomy examines the removed prostate and can provide a more complete assessment of tumor distribution and anatomic extent.
Initial Tissue Samples
Needle-Biopsy Report
Each separately submitted site or core may receive its own findings.
- Diagnosis and histologic type
- Gleason patterns, score, and Grade Group
- Percentage of pattern 4 when applicable
- Number of positive cores and amount of tumor
- Intraductal carcinoma, cribriform glands, or perineural invasion
After Prostate Removal
Radical-Prostatectomy Report
The entire removed gland and other submitted tissues may answer additional staging questions.
- Final Gleason score and Grade Group
- Tumor quantitation or dominant nodule findings
- Extraprostatic extension and bladder-neck invasion
- Seminal-vesicle invasion and surgical margins
- Regional lymph nodes and pathologic categories
Inside the Report
What Your Prostate Pathology Report May Tell You
The findings available depend on the specimen. A needle biopsy, TURP, simple prostatectomy, radical prostatectomy, and lymph-node report do not contain the same set of information.
Read the Gleason score together with the Grade Group.
The pattern order matters. Gleason 3+4=7 and 4+3=7 have the same total score but belong to different Grade Groups because the predominant pattern differs.
Diagnosis and Histologic Type
Most prostate cancers are acinar adenocarcinomas. The report identifies the tumor type and documents other components or variants when present.
Gleason Score and Grade Group
Gleason patterns are combined into a score and translated into Grade Group 1 through 5, providing two related ways to report grade.
Positive Cores and Sites
A biopsy report may state which locations contain cancer and how many cores are involved out of the number submitted.
Amount of Tumor
Tumor extent may be reported as millimeters, percentage of core involvement, total linear involvement, or other specimen-specific measurements.
Percentage of Pattern 4
For Gleason score 7 cancer, the percentage of pattern 4 may provide additional detail beyond the total score and Grade Group.
Intraductal Carcinoma
Intraductal carcinoma is reported separately. Pure intraductal carcinoma is not assigned a Gleason score or Grade Group.
Cribriform Glands
The presence of cribriform architecture may be reported when Gleason pattern 4 is identified, particularly in Gleason score 7 or 8 cancer.
Perineural or Other Invasion
A biopsy may mention tumor around or along a nerve. Extraprostatic or lymphatic/vascular invasion is recorded if identified in the submitted tissue.
Need Help Understanding These Findings?
Review the Gleason patterns, Grade Group, core involvement, important additional findings, specimen limitations, and pending results in your existing prostate pathology report during a secure virtual consultation.
Grade Group 1Gleason score 3+3=6
Grade Group 2Gleason score 3+4=7
Grade Group 3Gleason score 4+3=7
Grade Group 4Gleason score 8
Grade Group 5Gleason score 9 or 10
Understanding Tumor Grade
How Gleason Patterns Relate to Grade Group
Gleason grading describes how prostate adenocarcinoma is organised under the microscope. The first and second numbers describe different growth patterns, while Grade Group presents the result in a five-group system.
The Pattern Order Matters
In Gleason 3+4=7, pattern 3 predominates. In Gleason 4+3=7, pattern 4 predominates, placing the tumors in Grade Groups 2 and 3 respectively.
Pattern 4 Percentage Adds Detail
For Gleason score 7 cancer, the report may state the percentage of pattern 4. This is different from the percentage of the biopsy core involved by cancer.
Biopsy and Prostatectomy Grades May Differ
A biopsy samples part of the gland, while prostatectomy examines substantially more tissue. The later specimen may show a different grade or additional pattern.
After Radical Prostatectomy
Findings That Help Describe Pathologic Extent
A radical-prostatectomy report can document whether cancer remains confined to the prostate or involves specified structures beyond it. These findings are interpreted with grade, margins, nodes, PSA, imaging, and other clinical information.
Extraprostatic Extension
Extraprostatic extension means tumor extends beyond the prostate’s confines. The report may describe whether it is present and where it occurs.
Seminal-Vesicle Invasion
True invasion into the muscular wall of a seminal vesicle is documented separately and corresponds to a pT3b category.
Bladder-Neck Invasion
Microscopic bladder-neck invasion is included in pT3a, while invasion of adjacent structures in a pT4 category follows different criteria.
Surgical Margins
A positive margin means carcinoma reaches an inked specimen edge. The report may document the involved location, length, focality, and Gleason pattern.
Regional Lymph Nodes and pT Category
When pelvic nodes are submitted, the report records how many are examined and involved. Prostatectomy pT categories include pT2 for organ-confined disease, pT3a for extraprostatic extension or microscopic bladder-neck invasion, pT3b for seminal-vesicle invasion, and pT4 for invasion of specified adjacent structures.
Additional Testing
Immunohistochemistry, Tumor Testing, and Germline Genetics
Additional tests are not identical for every prostate cancer. Results may appear in the main pathology report, an addendum, a separate molecular report, or a genetics document.
Diagnostic Immunohistochemistry
Immunostains may help confirm prostatic origin, evaluate a small or unusual focus, or distinguish carcinoma from benign mimics. The panel varies by case.
IHCOrigin
Tumor Molecular Testing
Selected cases may undergo testing for DNA-repair pathway alterations, mismatch-repair deficiency, microsatellite instability, or other genomic findings.
MMR / MSITumor DNA
Inherited Genetic Testing
Germline testing evaluates inherited variants, including BRCA1, BRCA2, and other selected genes, through a separate genetics pathway when appropriate.
BRCA1/2Germline
Tumor testing and inherited genetic testing are not the same. Their meaning depends on the exact test, specimen, result, and clinical context. A consultation explains documented findings without predicting treatment response or recommending therapy.
Questions About an Immunostain or Molecular Addendum?
Get a patient-friendly explanation of studies already documented in your reports and identify which results may still be pending or reported separately.
Putting the Results Together
What Is Confirmed, Pending, or Dependent on Other Information?
A prostate pathology report may answer many important questions, but it does not provide the complete risk assessment or clinical plan on its own.
Confirmed in the Report
Documented Pathology Findings
The diagnosis, Gleason patterns and score, Grade Group, core involvement, tumor extent, intraductal or cribriform findings, and specimen-specific invasion findings may be documented when assessable.
May Still Be Pending
Addenda or Separate Results
Immunohistochemistry, molecular testing, outside consultation, germline testing, later prostatectomy, lymph-node findings, or another specimen may still be pending or separately reported.
Requires Wider Context
Clinical Stage and Treatment Planning
Clinical stage and treatment decisions may also require PSA, examination, imaging, health history, patient preferences, and evaluation by the treating care team.
How HONEST Pathology Helps
A Clearer Explanation of the Report You Already Have
A pathology report consultation helps you understand terminology and findings already documented, so you can approach conversations with your treating team with greater context and more focused questions.
Upload Your Report and Records
Submit the pathology report and relevant records requested for the consultation.
Meet Online With a Pathologist
Discuss the report during a private virtual appointment and ask questions about the documented findings.
Receive a Plain-Language Explanation
Better understand the terminology and prepare questions to discuss with your treating care team.
Consultation Scope
What the Consultation Includes and Excludes
A report explanation and a formal microscopic second opinion are different services. Clear boundaries help you choose the appropriate option.
The Consultation May Explain
- The documented diagnosis and prostate pathology terminology
- Differences between biopsy, TURP, and radical-prostatectomy reports
- Gleason patterns, Gleason score, Grade Group, and pattern 4 percentage
- Positive cores, tumor measurements, and specimen limitations
- Intraductal carcinoma, cribriform glands, perineural invasion, and other findings
- Margins, extraprostatic extension, seminal-vesicle invasion, nodes, and biomarkers
- Questions to discuss with your treating team
The Consultation Does Not Include
- A new pathology diagnosis or replacement interpretation
- A new written report or official document
- Clinical staging or risk classification from pathology alone
- Treatment prescribing or replacement of the medical care team
- Physical examination, PSA interpretation in isolation, or imaging review
- Microscopic slide review unless a separate pathology second-opinion service is ordered
Choosing the Right Service
Report Consultation or Formal Pathology Second Opinion?
The right option depends on whether you need help understanding written results or an independent review of pathology slides, tissue, or digital images.
Frequently Asked Questions
Questions About Prostate Cancer Pathology Reports
These answers provide general educational information. Individual reports vary according to specimen, procedure, tumor type, prior treatment, additional testing, and wider clinical situation.
What is the difference between Gleason score and Grade Group?
Gleason score combines two microscopic growth patterns, while Grade Group translates contemporary Gleason scores into five groups. Reports commonly provide both because they describe the same grade using related systems.
Why are Gleason 3+4=7 and 4+3=7 different?
The first number represents the predominant pattern. Gleason 3+4=7 is Grade Group 2, while 4+3=7 is Grade Group 3 because pattern 4 makes up the larger component.
What does the number of positive biopsy cores mean?
It indicates how many sampled cores contain cancer. The report may also state the involved sites and the amount of tumor in each core, but biopsy results do not measure the entire prostate.
What does perineural invasion mean on a prostate biopsy?
Perineural invasion means tumor is present around or along a nerve within the sampled tissue. It is one report finding and should be interpreted with grade, tumor extent, PSA, imaging, and the wider case.
What are intraductal carcinoma and cribriform glands?
These are specific microscopic findings that may be reported separately. Their significance depends on whether invasive carcinoma is present, its grade, the specimen, and the complete pathology context.
What does a positive surgical margin mean?
It means carcinoma reaches an inked edge of the radical-prostatectomy specimen. The report may identify the margin location, extent, focality, and Gleason pattern at the involved edge.
Will my PSA level appear in the pathology report?
PSA is a blood-test result, not a microscopic tissue finding. It may be included as clinical information, but it is interpreted by the treating team alongside pathology, imaging, examination, and other records.
When is a formal pathology second opinion more appropriate?
A formal second opinion may be appropriate when findings are complex, uncertain, unexpected, or when independent examination of the original slides or tissue could provide additional value.
Clearer Answers Begin Here
Understand the Findings in Your Prostate Pathology Report
Meet online with a pathologist who can explain the Gleason score, Grade Group, biopsy-core findings, prostatectomy findings, specimen limitations, molecular studies, and questions raised by your existing report.
Educational support only. This service does not replace your treating physician, urologist, urologic oncologist, surgeon, radiologist, genetic counselor, or medical care team.
